WASHINGTON - Tysabri could be coming back, at least in a limited capacity. That’s the growing consensus among many industry observers about the once heralded multiple sclerosis drug, which was pulled from the market a year ago after it was linked to a pair of deaths. (BioWorld Today) Read More
